Glybera(TM) Shows Long-Term Health Benefits

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced new data showing that a one-time administration of its lead product GlyberaTM results in significant long-term health benefits. Long-term follow-up data from two clinical trials show that one administration with GlyberaTM brings significant and clinically important reduction in acute pancreatitis in lipoprotein lipase deficient patients. Recurrent acute pancreatitis is the most debilitating complication of lipoprotein lipase deficiency (LPLD) and is associated with significant morbidity and mortality. These data were presented at the International Symposium on Atherosclerosis in Boston,...

Want to see the full article?

• Purchase this article for only $3.00